PICS (Post-Intensive Care Syndrome)

PICS (Post-Intensive Care Syndrome)

The journey through intensive care can be a harrowing experience for patients and their families. While the primary focus of intensive care units is to address life-threatening illnesses and stabilise patients, a significant and sometimes overlooked aspect is the aftermath of that care. Post-Intensive Care Syndrome (PICS) refers to the range of physical, cognitive, and…

Read More
EMCrit 404 – Facial Trauma

EMCrit 404 – Facial Trauma

The Paper Look Me in the Face and Tell Me That I Needed to Be Transferred: Defining the Criteria for Transferring Patients with Isolated Facial Injuries [10.1097/TA.0000000000004651]   Bellal Joseph, MD FACS Dr. Bellal Joseph is the Martin Gluck Endowed Professor of Surgery, Professor of Neurosurgery, Chief of General Surgery and Chief Division of Trauma,…

Read More
Critical Care Evidence Updates – May 2025 – The Bottom Line

Critical Care Evidence Updates – May 2025 – The Bottom Line

Randomised Controlled Trials A Multinational Randomized Trial of Mega-Dose Esomeprazole As Anti-Inflammatory Agent in Sepsis  Critical Care Medicine A pilot multicenter randomized controlled trial on individualized blood pressure targets versus standard care among critically ill patients with shock  Journal of Intensive Care A randomised, controlled, feasibility trial comparing vasopressors infused via peripheral cannula versus central…

Read More
Emergency Evidence Updates – May 2025 – The Bottom Line

Emergency Evidence Updates – May 2025 – The Bottom Line

Randomised Controlled Trials A non-inferiority randomised controlled trial of a Shorter Acetylcysteine Regimen for Paracetamol Overdose – the SARPO trial.  Journal of Hepatology Association of central capillary refill time with mortality in adult trauma patients: a secondary analysis of the crash-2 randomised controlled trial data  Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine Dorsal Digital…

Read More
Efficacy and Safety in a Phase 3 Trial

Efficacy and Safety in a Phase 3 Trial

What was it? Multicentre, double-blind, placebo-controlled phase 3 trial (TESTS), evaluating whether thymosin α1, animmunomodulatory drug, reduces 28-day all-cause mortality in adults with sepsis, conducted across 22 centresin China from September 2016 to December 2020. The Devil in the details! 1,106 adults (18–85 years) with sepsis per Sepsis-3 criteria, randomised 1:1 to thymosin α1 (n=552) or placebo (n=554), with 1,089 included in modified intention-to-treat analysis (thymosin α1: n=542, placebo: n=547). Subcut thymosin α1 (1.6 mg) vs placebo ‘lyophilised saline’ twice daily for 7 days (unless discontinued due to either discharge from…

Read More